Navigation Links
Statement from Kent Hill, USAID Assistant Administrator for Global Health, on the Observance of World Tuberculosis Day 2008

WASHINGTON, March 24 /PRNewswire-USNewswire/ -- The following are remarks by Kent Hill, USAID Assistant Administrator for Global Health, on the observance of World Tuberculosis Day 2008:

Although a cure for Tuberculosis (TB) has existed for more than half a century, TB remains one of three leading causes of death worldwide due to infectious disease. TB kills approximately 1.6 million people each year, while HIV/AIDS claims more than two million lives each year, and malaria kills more than one million people each year.

The U.S. Agency for International Development (USAID) has a clear and proven strategy to detect and treat people who suffer from TB. We are helping to make progress in prevention and control, and in 2005, the rate of new TB cases worldwide leveled off for the first time since the World Health Organization (WHO) began collecting data about the disease. Globally, the target of successfully treating 85 percent of TB cases has been met, and we continue to make steady progress toward the target of detecting 70 percent of all cases.

USAID is the lead U.S. government agency in international TB control programs, supporting efforts in 37 countries. USAID works in close partnership with the President's Emergency Plan for HIV/AIDS Relief, which is making significant investments in TB and HIV co-infection, with the Centers for Disease Control and Prevention, and with the National Institutes for Health.

The core of USAID's work in TB is focused on building the capacity of developing countries to implement effective programs to combat and control TB. Our programs support the implementation of the WHO Global Plan to Stop TB, which works to expand and strengthen basic TB programs as the key intervention for preventing and controlling drug-resistant TB. USAID is a founding member of the Stop TB partnership, which is comprised of a network of more than 500 international organizations, countries, donors from the public and private sectors, and nongovernmental and governmental organizations. Working closely with our partners, USAID recently increased the capacity to deliver Directly Observed Short Course (DOTS) treatment in more than 40 countries, including hard hit countries such as India, Indonesia, South Africa, and Russia

Our efforts are saving lives and making a real difference in affected communities, but much work remains to be done. The best approach we have to diagnose TB in resource limited settings is more than 100 years old, and the approach is only effective half of the time, even less so in HIV positive patients where TB is deadliest.

In addition, Eastern Europe and Asia are fighting an increasing prevalence of multiple drug resistance (MDR) to proven drug therapies. According to a new WHO report, MDR-TB rates are at their highest ever. MDR-TB requires treatment for 18 to 24 months with second-line drugs that are much less effective, poorly tolerated by the patient, and far more costly. Nearly 500,000 new cases of MDR-TB emerged globally in 2006.

Extensively drug-resistant (XDR) TB, a subset of MDR-TB caused by bacteria strains that are resistant to first-line and the most effective second-line drugs, has been recorded in 45 countries. XDR-TB is a virtually untreatable form of the respiratory disease. The true scale of the problem remains almost unknown because few countries are equipped to diagnose it.

Africa has the highest incidence of TB in the world, and Sub-Saharan Africa is battling the combined effects of TB and HIV/AIDS. TB is the leading cause of death for AIDS patients. In parts of Sub-Saharan Africa, rates of HIV co-infection among TB patients often exceed 50 percent.

The recent WHO report finds that some countries are making strides against the TB/HIV co-epidemic. Almost 700,000 TB patients were tested for HIV in 2006, up from 22,000 in 2002.

In addition to our work to strengthen basic TB programs, USAID has moved quickly to help countries and international partners respond to these new threats by assisting with drug-resistance surveys, building laboratory capacity to detect resistant strains, expanding country-level programs to treat MDR-TB patients, and supporting the Green Light Committee, which helps ensure that countries have effective programs to manage MDR-TB patients and second-line anti-TB drugs.

The threats of MDR-TB and XDR-TB have re-focused attention on the urgent need to develop more accurate and rapid diagnostics for TB, to develop new drugs effective against resistant strains, and to develop an effective TB vaccine. The U.S. is committed to work with country governments and the international community to successfully implement the WHO Global Plan to Stop TB. Together, we can continue to bring hope to the millions of people suffering from TB and work toward curing TB once and for all.

For more information on USAID's Global Health programs, please visit

Public Information: 202-712-4810

SOURCE U.S. Agency for International Development
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
(Date:10/13/2015)... ... , ... Curly Hair Solutions® is thrilled to be a ... featuring the newest products and services to hit the market for women. With ... to unveil their recent partnership with Trade Secrets, a leading Canadian beauty retailer. ...
(Date:10/12/2015)... TN (PRWEB) , ... October 13, 2015 , ... ... recipients of its biannual Heroes in Recovery Awards at Foundations Recovery Network’s Moments ... Recovery Network presented the one-of-a-kind awards to Noah Levine and Dean Dauphinais who ...
(Date:10/12/2015)... ... 12, 2015 , ... According to an article from ... particularly in the area of track and field, are at a significantly higher ... peers in the same age group. Dr. Steven Meier of Meier Orthopedic Sports ...
(Date:10/12/2015)... ... October 12, 2015 , ... American Family Care (AFC), the nation’s ... by opening its 151st medical center. Located at 606A Boll Weevil Circle in Enterprise, ... continue fulfilling our mission of making quality health care accessible and economical with the ...
(Date:10/12/2015)... ROSA, CA (PRWEB) , ... October 12, 2015 , ... ... (DSM) at no charge to qualified Managed Care Organizations (MCOs) in order to ... insight and analysis into their decision making process. In addition, the DSM is also ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... COSTA MESA, Calif. , Oct. 12, 2015 ... reaffirmed the accreditation of Harbor Compounding Pharmacy in ... accreditation is awarded in recognition of the pharmacy,s ... --> ... --> ...
(Date:10/12/2015)... Calif. , Oct. 12, 2015 /PRNewswire/ ... and Chief Scientific Officer of Asterias Biotherapeutics, ... company in the emerging field of regenerative ... webcast, sponsored in part by Asterias Biotherapeutics, ... Lebkowski will discuss the progress to date ...
(Date:10/12/2015)... , Oct. 12, 2015  In a Sutter ... the Journal of Neurology, Neurosurgery, and Psychiatry, the blood ... brain atrophy and cognitive decline in patients in the ... --> --> IVIG, extracted from the ... to amyloid, an abnormal brain protein found in patients ...
Breaking Medicine Technology: